" class="no-js "lang="en-US"> Develco Pharma - Medtech Alert
Monday, September 22, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Develco Pharma | Pharmtech Focus

Develco Pharma

About Develco Pharma

Develco Pharma
Develco Pharma is a privately owned company operating in the field of development and manufacture of pharmaceutical products. We develop and produce difficult to make, innovative formulations of drugs, with the goal to improve quality of life and success of the company.

Related Story

Clinical Trials

 HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-resistant Depression (TRD) | Pharmtech Focus

HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-resistant Depression (TRD)

April 1 2022

HMNC Brain Health (“HMNC” or the “Company”), a global clinical stage biopharmaceutical company pioneering the […]